161.21
+0.715(+0.45%)
Currency In USD
Address
2100 Wharton Street
Pittsburgh, PA 15203
United States of America
Phone
412 586 5830
Website
Sector
Healthcare
Industry
Biotechnology
Employees
229
First IPO Date
September 20, 2017
| Name | Title | Pay | Year Born |
| Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & Chief Executive Officer | 1.32M | 1965 |
| Ms. Kathryn A. Romano CPA | Executive Vice President & Chief Accounting Officer | 614,867 | 1981 |
| Ms. Suma M. Krishnan | Founder, President of R&D and Director | 895,325 | 1965 |
| Mr. John Thomas | General Counsel & Corporate Secretary | 0 | N/A |
| Mr. John Karakkal | Vice President of North American Sales & Marketing | 0 | N/A |
| Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development | 0 | N/A |
| Mr. David Chien | Senior Vice President of Clinical Development | 0 | N/A |
| Mr. Laurent Goux | Senior Vice President & GM of Europe | 0 | N/A |
| Ms. Christine Wilson | Head of U.S. Sales & Marketing | 0 | N/A |
| Mr. Josh Suskin | Director of Human Resources & Operations | 0 | N/A |
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.